Pfizer Makes Major Moves with 3SBio Deal and Dividend Increase

Published 8 hours agoPFE

Pfizer Makes Major Moves with 3SBio Deal and Dividend Increase

Pfizer has reached a major licensing agreement with Chinese biotech company 3SBio for a promising bispecific cancer drug, SSGJ-707. The deal involves a $1.25 billion upfront payment and potential milestones worth up to $4.8 billion. In addition, Pfizer plans to invest $100 million in 3SBio, gaining rights to the drug outside China, with Phase III trials set to kick off in China later this year, according to Axios.

In another key development, Pfizer announced an increase in its quarterly cash dividend to $0.43 per share for the first quarter of 2025. This will mark its 345th consecutive quarterly dividend, reinforcing the company's robust financial health and its ongoing dedication to delivering shareholder value, as stated in a company press release.

Furthermore, Pfizer is pushing forward with a new cost-cutting initiative aimed at trimming approximately $1.5 billion from its expenses by 2027. This plan includes changes to operational processes, network structures, and product lines. Alongside these financial strategies, Pfizer continues to focus on oncology research, highlighting more than 60 presentations at the upcoming ASCO Annual Meeting, showcasing its significant progress in cancer treatment research.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Jefferies Lifts Verint Price Target Despite Revenue Shortfall

Jefferies Lifts Verint Price Target Despite Revenue Shortfall

29 minutes agoVRNT

Jefferies Financial Group has maintained its 'Hold' rating for Verint Systems while increasing the company's price target from $28 to $34. This adjustment comes after Verint's fourth-quarter earnings report, which showed a revenue shortfall due to delays in significant deals. As reported by Investing.com, Verint's recent earnings noted a notable revenue shortfall, with a delay in a single large deal contributing $18 million to a total $24 million shortfall. Nevertheless, Verint's Annual Recurring Revenue (ARR) rose by 5% in the fourth quarter, exceeding the anticipated 4% growth. While Jefferies' elevated price target reflects optimism about Verint's potential, especially in AI-driven customer engagement, the company's stock performance will depend on its ability to close these delayed deals. Investors are closely watching Verint's revenue recognition strategy as it moves into the new fiscal year.

Jefferies Raises Paycom Software's Price Target Amid Positive Sector Outlook

Jefferies Raises Paycom Software's Price Target Amid Positive Sector Outlook

44 minutes agoPAYC

Jefferies Financial Group has increased its price target for Paycom Software, Inc. from $170 to $175 while maintaining a 'Hold' rating on the stock. This move suggests a cautiously optimistic view on the company's performance in the competitive payroll sector. The decision by Jefferies comes as analysts adopt more reasonable expectations, supported by the current valuation multiples within the payroll industry. According to Nasdaq, this adjustment aligns with broader trends where analysts are reassessing forecasts as employment figures continue to show resilience. Paycom Software's recent stock performance supports this assessment, with shares trading at $212.83 as of October 31, 2024. This falls within a 52-week range of $139.50 to $247.42, indicating a solid standing within the market. Techdows reported these figures following Jefferies' announcement, highlighting the confidence in Paycom's potential growth in the immediate future.

Jefferies Boosts Paychex Price Target Amid Strong Performance

Jefferies Boosts Paychex Price Target Amid Strong Performance

59 minutes agoPAYX

Jefferies Financial Group has recently raised its price target for Paychex, Inc. from $120.00 to $130.00, while maintaining a "Hold" rating. This move highlights a positive outlook for the company, supported by strong financial results in the latest fiscal quarter. Paychex's impressive performance is underpinned by a 6% increase in revenue and an 8% rise in earnings per share, as reported for its most recent fiscal quarter. These figures reinforce its reputation as a financially healthy entity. According to American Banking News, the consensus among analysts remains a "Hold" rating, with an average price target of $130.77. The company is recognized as a solid, defensive growth stock, often sustaining a stable growth rate in earnings per share, even in varied market conditions. These latest adjustments and ratings reflect confidence in Paychex's ability to maintain its strong market position.

Nucor Stock Dips Amid Market Challenges

Nucor Stock Dips Amid Market Challenges

Nucor Corporation (NYSE: NUE) is currently trading at $108.49 per share, marking a slight dip of 2.03% from its previous close. This development comes as the steel industry faces several challenges, including declining hot-rolled coil prices. During the most recent trading session, Nucor's intraday high and low were $111.18 and $106.96, respectively, with a trading volume of approximately 3.9 million shares. Looking at the company's recent financial achievements, Nucor reported a strong first-quarter performance in 2025, with adjusted profits of 77 cents per share, surpassing analysts' expectations of 64 cents. The company's revenue reached $7.83 billion, outperforming the anticipated $7.23 billion. However, the fourth quarter of 2024 saw a notable decrease in revenue and earnings due to lower steel prices, with earnings per share dropping to $1.22 from $3.16 the year before, as reported by Reuters. Despite current market headwinds, Morgan Stanley has upgraded Nucor's stock to "Overweight," highlighting strong earnings growth and cash generation, although noting its discounted valuation compared to peers. Additionally, Nucor is committed to shareholder value, boasting 52 consecutive years of dividend increases and a 1.4% current dividend yield. The company plans to invest $6.5 billion through 2027 in various growth projects, aiming for long-term growth despite potential short-term financial constraints.